Please login to the form below

Not currently logged in


This page shows the latest Proximagen news and features for those working in and with pharma, biotech and healthcare.

BenevolentAI raises $115m to fund drug development

BenevolentAI raises $115m to fund drug development

BenevolentAI currently has 22 validated drug candidate programmes on the go, according to chief executive Ken Mulvany, formerly CEO of Proximagen, who describes the company as “a fully integrated, AI enabled

Latest news

  • Artificial intelligence firm licenses Janssen candidates for development Artificial intelligence firm licenses Janssen candidates for development

    BenevolentAI was founded in 2013 as a spin-out of pharmaceutical company Proximagen.

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    But adds inflammation research agreement with Proximagen.  . Roche has opted to discontinue an alliance with Swiss biopharma company Polyphor to develop antibiotics for resistant infections. ... VAP-1 is a cell-adhesion molecule that may have a role to

  • High hopes

    Proximagen eyes AIM. Another university spin-out, Proximagen, is also planning to list on the stock market.

  • The waiting game

    Encouraging maiden interim results from Proximagen Neuroscience, a drug company specialising in neurodegenerative diseases, gave its depressed share price a useful lift.

  • Pharma stocks battle on

    funds. Meanwhile, Proximagen, a drug developer, made a good debut on AIM with its shares up 6p on the 148p offer price.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    sell to focus on its other companies Proximagen, an early-stage drug discovery and development company, and Pairnomix, a genetics research company.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...